Healthy 18-year old dies after being vaccinated with AstraZeneca

An 18-year-old woman started experiencing symptoms 9 days after vaccination. 


She checked into the emergency room complaining of severe headaches and extreme light sensitivity. A CT scan and neurological tests found nothing, so doctors discharged her and recommended to return in 15 days for further tests.

But she returned to the hospital just two days later. She now suffered from paralysis in at least one part of her body.

This time she was diagnosed with cavernous sinus thrombosis, meaning a blood clot in the space between the eye sockets and brain. It blocked the primary vein between her head and the heart. Doctors also discovered that she had a brain bleed. She underwent two surgeries, one to remove the blood clot and the second to relieve pressure in her head caused by the bleeding. But the damage was done. She died 5 days later, 

She was previously healthy and was not taking any medications. 


REFERENCES

Camilla, who died at the age of 18 after AstraZeneca: "She was healthy, died of an adverse effect of the vaccine" - The Union Sarda.it (unionesarda.it)

Camilla Canepa: 18-year-old Italian woman develops blood clots, dead two weeks after experimental AstraZeneca shot - The COVID Blog™

Camilla Canepa, the 18-year-old who died of thrombosis after the AstraZeneca vaccine, will donate organs (italy-24.com)

The father of Camilla Canepa, the 18-year-old who died after the AstraZeneca vaccine, died - L'Unione Sarda English


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative. This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral loads and last for at least 60 da
Read more